table of content
1 Introduction to Research & Analysis Reports
1.1 Long-Acting Injectable (LAI) Antipsychotic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long-Acting Injectable (LAI) Antipsychotic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long-Acting Injectable (LAI) Antipsychotic Overall Market Size
2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size: 2023 VS 2030
2.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Long-Acting Injectable (LAI) Antipsychotic Players in Global Market
3.2 Top Global Long-Acting Injectable (LAI) Antipsychotic Companies Ranked by Revenue
3.3 Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Companies
3.4 Top 3 and Top 5 Long-Acting Injectable (LAI) Antipsychotic Companies in Global Market, by Revenue in 2023
3.5 Global Companies Long-Acting Injectable (LAI) Antipsychotic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long-Acting Injectable (LAI) Antipsychotic Players in Global Market
3.6.1 List of Global Tier 1 Long-Acting Injectable (LAI) Antipsychotic Companies
3.6.2 List of Global Tier 2 and Tier 3 Long-Acting Injectable (LAI) Antipsychotic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Market Size Markets, 2023 & 2030
4.1.2 Aripiprazole
4.1.3 Fluphenazine
4.1.4 Haloperidol
4.1.5 Others
4.2 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
4.2.1 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
4.2.2 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
4.2.3 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Others
5.2 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
5.2.1 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
5.2.2 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
5.2.3 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Market Size, 2023 & 2030
6.2 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
6.2.1 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
6.2.2 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
6.2.3 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.3.2 US Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.3.3 Canada Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.3.4 Mexico Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.4.2 Germany Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.3 France Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.4 U.K. Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.5 Italy Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.6 Russia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.7 Nordic Countries Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.8 Benelux Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.5.2 China Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.3 Japan Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.4 South Korea Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.5 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.6 India Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.6.2 Brazil Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.6.3 Argentina Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.7.2 Turkey Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.3 Israel Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.4 Saudi Arabia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.5 UAE Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
7 Long-Acting Injectable (LAI) Antipsychotic Companies Profiles
7.1 Alkermes
7.1.1 Alkermes Company Summary
7.1.2 Alkermes Business Overview
7.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.1.4 Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.1.5 Alkermes Key News & Latest Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Company Summary
7.2.2 Eli Lilly and Company Business Overview
7.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.2.4 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.2.5 Eli Lilly and Company Key News & Latest Developments
7.3 Janssen Global Services, LLC
7.3.1 Janssen Global Services, LLC Company Summary
7.3.2 Janssen Global Services, LLC Business Overview
7.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.3.4 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.3.5 Janssen Global Services, LLC Key News & Latest Developments
7.4 Abilify Maintena
7.4.1 Abilify Maintena Company Summary
7.4.2 Abilify Maintena Business Overview
7.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.4.4 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.4.5 Abilify Maintena Key News & Latest Developments
7.5 Haldol
7.5.1 Haldol Company Summary
7.5.2 Haldol Business Overview
7.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.5.4 Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.5.5 Haldol Key News & Latest Developments
7.6 Otsuka Pharmaceutical
7.6.1 Otsuka Pharmaceutical Company Summary
7.6.2 Otsuka Pharmaceutical Business Overview
7.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.6.4 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.6.5 Otsuka Pharmaceutical Key News & Latest Developments
7.7 Aristada
7.7.1 Aristada Company Summary
7.7.2 Aristada Business Overview
7.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.7.4 Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.7.5 Aristada Key News & Latest Developments
7.8 Prolixin
7.8.1 Prolixin Company Summary
7.8.2 Prolixin Business Overview
7.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.8.4 Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.8.5 Prolixin Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
